ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 114 filers reported holding ESPERION THERAPEUTICS INC NE in Q4 2015. The put-call ratio across all filers is 1.12 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $41,957,000 | +8.3% | 837,125 | 0.0% | 6.89% | +3.9% |
| Q2 2017 | $38,742,000 | +31.1% | 837,125 | 0.0% | 6.64% | +23.3% |
| Q1 2017 | $29,559,000 | +44.2% | 837,125 | -48.9% | 5.38% | +12.9% |
| Q4 2016 | $20,497,000 | -9.6% | 1,637,125 | 0.0% | 4.76% | +2.0% |
| Q3 2016 | $22,674,000 | +40.2% | 1,637,125 | 0.0% | 4.67% | +22.3% |
| Q2 2016 | $16,175,000 | -41.6% | 1,637,125 | 0.0% | 3.82% | -31.1% |
| Q1 2016 | $27,684,000 | -24.0% | 1,637,125 | 0.0% | 5.54% | -11.8% |
| Q4 2015 | $36,442,000 | -5.6% | 1,637,125 | 0.0% | 6.28% | -7.4% |
| Q3 2015 | $38,620,000 | -71.1% | 1,637,125 | 0.0% | 6.79% | -65.9% |
| Q2 2015 | $133,851,000 | -29.6% | 1,637,125 | -20.3% | 19.93% | -19.9% |
| Q1 2015 | $190,255,000 | +129.0% | 2,054,594 | 0.0% | 24.90% | +97.7% |
| Q4 2014 | $83,088,000 | +65.3% | 2,054,594 | 0.0% | 12.60% | +29.2% |
| Q3 2014 | $50,260,000 | +54.5% | 2,054,594 | 0.0% | 9.75% | +3.6% |
| Q2 2014 | $32,540,000 | – | 2,054,594 | – | 9.40% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 2,818,835 | $59,618,000 | 21.09% |
| Bellevue Group AG | 4,519,164 | $95,580,000 | 0.93% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 1,713,176 | $36,234,000 | 0.84% |
| Rhenman & Partners Asset Management AB | 572,267 | $12,103,000 | 0.82% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 64,434 | $1,363,000 | 0.45% |
| Boxer Capital, LLC | 500,000 | $10,575,000 | 0.37% |
| EMC Capital Management | 27,566 | $583,000 | 0.33% |
| WASATCH ADVISORS LP | 3,766,935 | $79,671,000 | 0.32% |
| Avidity Partners Management LP | 400,000 | $8,460,000 | 0.23% |
| Cinctive Capital Management LP | 186,170 | $3,937,000 | 0.18% |